Novartis: Real-world Evidence Confirms Efficacy Of Cosentyx - Quick Facts

Shutterstock photo

(RTTNews.com) - Novartis ( NVS ) announced new data from multiple real-world sources in moderate-to-severe plaque psoriasis, which confirm Cosentyx (secukinumab) efficacy and safety in clinical practice is comparable to previously reported clinical studies. The company said real-world evidence also confirmed the additional benefits of Cosentyx with PROSPECT, the largest prospective real-world analysis on Cosentyx to date, demonstrating a pronounced improvement in quality of life in a real-world setting.

"This large program of real-world evidence adds to the robust body of clinical data supporting the use of Cosentyx for psoriasis," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology.

Read the original article on RTTNews (http://www.rttnews.com/2934425/novartis-real-world-evidence-confirms-efficacy-of-cosentyx-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks , Commodities
Referenced Symbols: NVS

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?